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8ABSTRACT
Cardiac allograft arteriosclerosis (TxCAD) is a manifestation of chronic rejection and is
the main reason for poor long-term survival among heart transplant recipients. Typical
histological features for TxCAD are neointimal formation and mild perivascular
inflammation affecting the whole arterial network of the allograft. The prevalence of
TxCAD by coronary angiography is 32% at 5 years following transplantation. The
pathophysiological mechanisms of TxCAD are largely unknown and there are no tools to
prevent the disease today.
TxCAD probably begins with endothelial cell injuries of immunological or
nonimmunological etiology that act together to accumulate T cells and macrophages into
subendothelial space. Inflammatory and endothelial cells secrete growth factors which in
proinflammatory cytokine environment activate medial smooth muscle cells to migrate into
neointima and to proliferate. Recent findings indicate, however, that obliterative neointimal
smooth muscle cells may also originate from circulatory stem cells. To identify new
potential therapeutic approaches to prevent TxCAD we investigated crosstalk between
platelet-derived growth factor and proinflammatory cytokines during the development of
TxCAD using experimental rabbit and rat heart transplantation models and in vitro
experiments.
This study establishes the central role of platelet-derived growth factor receptor activation
in TxCAD and suggests that proinflammatory cytokines, such as tumor necrosis factor-α,
interleukin-1β, and endothelin-1 promote TxCAD via the platelet-derived growth factor
receptor upregulation. Inhibition of platelet-derived growth factor receptor activation
attenuated TxCAD also in hypercholesterolemic environment suggesting potential in
clinical TxCAD as well. However, blocking of platelet-derived growth factor signaling is
not sufficient to totally prevent TxCAD indicating that combined inhibition of growth
factors may be needed for efficient intervention.
9INTRODUCTION
Cardiac allograft arteriosclerosis, i.e., transplant coronary artery disease (TxCAD) is a
manifestation of chronic rejection and is the main single reason for poor long-term
survival of heart transplant recipients (Hertz et al., 2002). In autopsy studies, virtually all
heart allografts have histological evidence of TxCAD already one year after transplantation
(Johnson et al., 1989). The prevalence of TxCAD by coronary angiography is 32% at 5
years following transplantation (Hertz et al., 2002), its pathophysiological mechanisms are
largely unknown, and there are no tools to prevent the disease today.
Typical histological features of TxCAD are neointimal formation and mild perivascular
inflammation affecting the whole arterial network of the allograft (Johnson et al., 1989).
The final outcome of TxCAD is ischemic damage of the myocardium and graft failure due
to insufficient blood flow through narrowed arterial lumens. TxCAD probably begins with
minor damage in the vascular wall, and cytokines released in response to injury result in an
inflammatory response. Endothelial cell injury of immunological or nonimmunological
etiology accumulates T cells and macrophages into the vascular wall initiating T cell-
governed alloimmune processes. This culminates in smooth muscle cell (SMC) migration
from the media to the intima and subsequent proliferation in the intima (Libby and Pober,
2001). Recent findings indicate, however, that neointimal SMC in the vessel wall may also
originate from circulatory stem cells (Hillebrands et al., 2000; Li et al., 2001; Saiura et al.,
2001; Shimizu et al., 2001). Final SMC regulating factors are probably growth factors
acting in the presence of proinflammatory cytokines (Häyry et al., 1993).
The purpose of this study was to investigate crosstalk between platelet-derived growth
factor (PDGF) and proinflammatory cytokines, tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β) and endothelin-1 (ET-1) during the development of TxCAD and to
identify new therapeutic approaches to prevent this fibroproliferative disorder using
experimental rabbit and rat heart transplantation models and in vitro experiments.
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REVIEW OF THE LITERATURE
1. Introduction to immunobiology of heart allograft rejection
Allograft rejection is antigen specific, cell mediated immune response concerning virtually
all cell types in the defensive machinery. T cells have a central role in this complicated
series of events. They may initiate the process by recognizing foreign antigens, expand
clonally and finally organize destruction of the allograft with the aid of unspecific
inflammatory cells. In transplantation, T cells act according to their nature in order to
recognize and eliminate suspicious cells as in classic immunity. However, the major
difference between classic T cell immune activation and alloimmune activation is the
enormous strength of alloimmune activation (VanBuskirk et al., 1997).
1.1. Transplantation antigens
The first step in alloimmune activation is recognition of foreign antigen by cell surface
receptor on T cell (TCR). This recognition is possible only if specific TCRs exist in the
recipient´s collection of T cell clones. The counterpart of TCR is a fragment of foreign
protein associated with the major histocompability complex (MHC) molecule on the
surface of antigen presenting cell (APC). The MHC molecules are of fundamental
importance in T cell activation. Highly polymorphic genes encode them, and in
transplantation, MHC disparity between donor and recipient is the most important factor
determining whether the allograft is rejected or not. MHC molecules are divided into Class
I and Class II according to their structure, function and expression. Class I molecules are
expressed by all nucleated cells, whereas Class II molecules are expressed by professional
APC such as B cells, macrophages and dendritic cells (Daar et al., 1984a; Daar et al.,
1984b). MHC molecules bind either endogenous or exogenous peptide and are actively
transported to cell surface. Class I MHC molecules bind peptides derived from proteins
synthesized by host cells and interact with the CD8 molecules on T cells (Salter et al.,
1989) while class II MHC molecules bind fragments from phagocytosed proteins and
interact with the CD4 molecules on T cells (Engleman et al., 1981). The amount of both
MHC molecules is inducible in response to cytokines thereby magnifying the immune
response (Vegh et al., 1993; Kittur et al., 2002).
1.2. Antigen presenting cell and T cell activation
Almost all cells are capable of presenting antigen for either CD4+ or CD8+ T cells. The
term APC is, however, reserved for bone marrow derived ”professional” antigen-
presenting cells. APC have the capacity of handling and transporting foreign protein to the
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proximity of naive T cells. After migration to lymphatic tissue, APC serve as a platform for
T cells to survey antigens. Triggering of TCR alone is, however, not sufficient to cause T
cell activation. APC are able to provide the necessary costimulation of which most
important is the costimulatory molecule B7 on the APC activating CD28 on T cells. TCR
activation without costimulation results in a quiescent state called anergy (Harding et al.,
1992). Communication between APC and T cells is reciprocal. T cell activation increases
adhesion molecule and MHC class II density on the APC surface making T cell
recognition even easier. CD40L-CD40 interaction between T and B cells promotes specific
antibody production and activates B cells (Grabstein et al., 1993). The most important
cytokine produced by activated T cells is IL-2, growth factor for T cells acting in an
autocrine or paracrine way.
1.3. T cell functions in allograft rejection
In cardiac transplantation, a considerable amount of passenger leucocytes are transplanted
along with the allograft. This second set of APC has a foreign peptide associated with a
foreign MHC class II on the cell surface. Passenger leucocytes can be found from
recipient lymphatics soon after transplantation and are surveyed by recipient naive CD4+
T cells (Nemlander et al., 1982; Larsen et al., 1990). This interaction is called direct
antigen presentation and it causes extremely strong and exceptional T cell activation. The
precursor frequency of T cells for foreign MHC+foreign peptide is roughly 100-fold
higher than that of any pathogen derived antigen (Lindahl and Wilson, 1977). CD8+ cells
are exceptionally able to interact with Class II molecule and act as helper T cells, and
CD4+ cells interact with Class I molecule and perform cytotoxic activity that normally
belong to CD8+ T cells (Sabatine and Auchicloss Jr., 1996). Foreign peptides can also be
presented to T cells together with self MHC class II (Sherwood et al., 1986). This
conventional way of antigen presentation is called an indirect pathway. These two
pathways are both capable of causing acute allograft rejection and may act either alone or
together (Rosenberg et al., 1987; Zijlstra et al., 1992). However, donor APC supply is
limited and finally exhausted increasing the importance of the indirect pathway later in the
allorecognition process
1.4. T cell cytokines
Once fully activated, naive CD4+ cells produce IL-2 and a number of other cytokines and
cytokine receptors which modulate both immune response and unspecific inflammatory
response. Binding of IL-2 to its receptor results in clonal expansion of activated T cells
which are able to recognize the graft. CD8+ T cells perform direct cytolytic attacks against
foreign-recognized cells, whereas cytokines such as IFN-γ and TNF-α produced by
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CD4+ helper T cells modulate local unspecific inflammatory response including NK cells,
macrophages and dendritic cells. Cytokines stimulate also endothelial cells to facilitate
adhesion and migration of immune and inflammatory cells (Pober et al., 1986). CD4+ T
cells are further divided in two groups according their profile of cytokine production. Th1
clones have been associated with the production of IL-2, IFN-γ and TNF-β, while Th2
clones with that of IL-4, IL-5 and IL-6. Both cell types produce IL-3, granulocyte-
monocyte colony stimulating factor (GM-CSF) and TNF-α (Mosmann et al., 1986).
Cytokines produced by the Th1 cells recruit and activate B-cells and macrophages
augmenting alloimmune response both in cell-mediated and humoral fashion (Sayegh et
al., 1995). Th2 cells, in turn, are suggested to reduce cell-mediated alloimmune response,
and upregulation of Th2 cytokines is associated with prolonged cardiac allograft survival
in experimental models (Shirwan et al., 1998).
1.5. Humoral alloimmune response
The role of alloantibodies in allograft rejection is incompletely understood. However, they
are present in acute and chronic rejection and predict TxCAD in clinical and experimental
settings (Russell et al., 1994; Shi et al., 1996; Fredrich et al., 1999). Hyperacute rejection,
the rapid onset of immunologic reaction and loss of graft function during the first hours
after transplantation, is mediated by alloantibodies and complement (Kissmeyer-Nielsen et
al., 1966). Primary and most significant known targets of alloantibodies are MHC
molecules and endothelial cell antigens (Cerilli et al., 1985; Scornik et al., 1992). In
allograft rejection, humoral and cellular immune responses can act simultaneously and are
closely connected via T and B cell interactions. Briefly, the Ig receptor of B cells attaches
to a suitable antigen, which is internalized into a B cell and presented to a CD4+ T cell. In
other words, B cells act as APC for CD4+ T cells, which in turn activate B cells via the cell
surface molecule CD40 ligand-receptor interaction to proliferate and to produce antibodies
(Linsley et al., 1990).
2. Introduction to clinical heart transplantation
Heart transplantation has been under expedition since the beginning of 20th century. It
took decades and numerous experimental transplantations with large animals before
adequate surgical devices and techniques were achieved to perform orthotopic heart
transplantation in 1959. In 1967, Christiaan Barnard shocked the world by performing the
first successful human heart transplantation (Barnard, 1967). The following year, several
centers around the world included heart transplantation in their clinical programs
(Patterson and Patterson, 1997). Although the concept of acute rejection and the need for
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immunosuppression for engrafted patients was known, immunosuppression was primitive
by today’s standards and with rare exceptions all patients died in a few months either in
acute rejection or infection. Hence, initial enthusiasm for the life-saving heart
transplantation waned and virtually no heart transplantations were performed until 1980´s
(Patterson and Patterson, 1997). The turnover point was the introduction of a new T cell-
targeted immunosuppressant, cyclosporine A (CsA), into regular medication of transplant
patients (Borel et al., 1976; Griffith et al., 1982). The whole nature of postoperative
treatment changed when, instead of high dose steroid and azathioprine treatment, focused
immunosuppression with CsA, low dose corticosteroid, and azathioprine was introduced.
Suddenly acute rejection episodes could be controlled without fatal infections leading to
dramatic improvement in short-term survival. The current 5-year survival rate in heart
transplantation is up to 75%. Despite improved early survival, the long-term prognosis has
not substantially improved over the past two decades because of the unavoidable course of
chronic rejection (Hertz et al., 2002).
2.1. Indications and outcomes
According to the Registry of International Society for Heart and Lung Transplantation
(ISHLT) approximately 60 000 heart transplantations have been performed so far, and the
main diagnoses leading to heart transplantation are idiopathic and ischemic
cardiomyopathy. Patient half-life for all patients transplanted between 1982 and 2001 was
9.3 years, and after the first year survival declines at a constant rate of 4% per year (Hertz
et al., 2002, Fig 1.).
2.2. Complications and comorbidities
Until recently, acute rejection has been the leading single cause of death during the first
posttransplant year. From 1 to 3 years after transplantation, rejection, malignancy, TxCAD
and miscellaneous other cases are equally responsible for deaths. After five years, TxCAD
is the leading cause accounting for 31% of all deaths (Taylor et al., 2003).
Survivors of heart transplantation have high incidence of comorbidities. Of the patients
72% develop hypertension, 49% hyperlipidemia and 24% diabetes during the first
posttransplant year. By year 5, prevalences of hypertension, hyperlipidemia and diabetes
increase up to 95%, 81%, and 32%, respectively. The prevalence of TxCAD is 32% by
year 5 (Hertz et al., 2002, Fig 1.).
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Figure 1. According to the Registry of the International Society for Heart and Lung Transplantation: (A)
survival for heart transplants performed between 1982 and 2001, (B) prevalence of TxCAD and
malignancies after heart transplantation. Reproduced from Hertz et al. J Heart Lung Transplant.
2002;21:950-970, through the courtesy of Elsevier Inc., New York, NY.
3. Cardiac allograft arteriosclerosis (TxCAD)
3.1. Epidemiology
TxCAD is a progressive complication affecting virtually all engrafted patients and is the
leading cause of death after five years, accounting for 31% of all deaths (Taylor et al.,
2003). TxCAD affects the graft independent of the recipients´ age, sex or even CsA
immunosuppression and it can develop as early as three months after transplantation (Gao
et al., 1988; Sharples et al., 1991; Dent et al., 2000). Five years after operation, TxCAD is
detected by angiography in 32% of recipients (Hertz et al., 2002) while almost all patients
have histological evidence of the disease already one year after cardiac transplantation
(Johnson et al., 1991).
3.2. Clinical presentation
TxCAD is usually clinically silent due to denervation of the transplanted heart, until it has
progressed to end-stage disease (Gao et al., 1987). The usual manifestations are
congestive heart failure, life-threatening arrhythmias, or a sudden death. The outcome is
because of the ischemic nature of the disease; the whole arterial network is affected by
intimal thickening and luminal narrowing resulting in microinfarctions and ischemic
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regions in the myocardium. Due to the diffuse concentric nature of the arterial lesions that
reach the smallest intramyocardial branches, the only definitive tool for diagnosis is
autopsy. However, although angiography is at its best in imaging narrowing in proximal
epicardial coronaries, it can also be used for diagnosis of TxCAD if serially performed
(Fig.2). Currently, intracoronary ultrasound (Fig.3) is the most sensitive invasive tool to
identify TxCAD in vivo (Pinto et al., 1992; St Goar et al., 1992). The disadvantage of
intracoronary ultrasound is its limited entrance into smaller coronary branches.
Figure 2 . Sequential coronary angiographies at 1- and 3-years follow-up after cardiac transplantation.
Left panels: a nearly normal left (a) and right (c) coronary arteriography. Right panels: severe TxCAD
progression after 3 years can be seen both in left (b) and right (d) coronaries. Klow et al. Acta radiologica.
1998;39:652-662, reproduced through the courtesy of Blackwell Publishing, Copenhagen, Denmark.
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Figure 3 . Intracoronary ultrasound images from heart transplant patients. A, Minimal intimal
proliferation, indicated by the thin area between black and white arrow. B, Marked intimal proliferation,
indicated by the thick area between white and black arrow. Deng et al. Circulation. 1995;91:1647-1654,
reproduced through the courtesy of Lippincott Williams & Wilkins, Baltimore, MD.
3.3. Pathology
The histological features of TxCAD are persistent mild perivascular inflammation, intimal
thickening and fibrosis. In more advanced stages of the disease, intimal thickening affects
the entire arterial network from large epicardial coronaries to the smallest intramyocardial
branches (Fig.4.). Obliterative intimal mass is cell-rich consisting mainly of SMC and
extracellular matrix. There are also a few T lymphocytes and macrophages as well as rare
lipid deposits in the intima, while calcifications are virtually nonexistent (Johnson et al.,
1991). In contrast to conventional coronary artery disease (CAD), the nature of the lesions
in TxCAD is diffuse and concentric rather than focal and eccentric. Internal elastic lamina
is almost intact with occasional breaks (Johnson et al., 1991). Neointimal SMC are
thought to be of medial origin. However, recent clinical and experimental findings indicate
that neointimal SMC in aorta and heart allograft arteriosclerosis may also originate from
the recipient´s bone marrow stem cells (Hillebrands et al., 2000; Li et al., 2001; Saiura et
al., 2001; Shimizu et al., 2001).
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Figure 4. A transverse section from a human endomyocardial biopsy showing a small totally occluded
intramyocardial branch of coronary artery representing progressed state of TxCAD. Hematoxylin-
eosin+elastic van Giesen staining (kindly provided by Prof. Timo Paavonen, University of Helsinki).
3.4. The response-to-injury theory
The etiology leading to TxCAD is clearly multifactorial (Libby and Pober, 2001).
According to the response-to-injury theory, endothelial injury is the central initiating
element of the atherosclerotic process (Ross, 1993). Endothelial dysfunction is caused by
turbulent shear stress, viral infection, hypercholesterolemia, free radicals induced by
smoking, hypertension, diabetes or a combination of these (Ross, 1993). Fatty streaks are
the earliest lesions in conventional atherosclerosis consisting of lipid-laden macrophages
and of T cells. Later they are joined by various numbers of SMC. Initially T cells and
monocytes are recruited from circulation into the vessel wall by chemoattractants derived
from damaged endothelium. T cells and macrophages recruited to the site of inflammation
secrete in turn cytokines and growth factors inducing endothelial cells to express adhesion
molecules thus enabling more inflammatory cells to attach and migrate into the vessel wall.
In the modified response-to-injury theory applied for TxCAD, continuous inflammation
and especially growth factor stimulation in proinflammatory cytokine environment finally
activate the normally quiescent medial SMC to migrate into the intima and to proliferate
there forming a typical appearance of a diffuse concentric lesion in the vessel wall (Häyry
et al., 1993). However, as stated earlier, new findings in experimental TxCAD indicate that
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a fraction of SMC in the neointima originates from the recipient´s bone marrow cells
(Hillebrands et al., 2003). Thus, similar mechanisms may act both in ordinary
atherosclerosis and in TxCAD, where the major difference from ordinary atherosclerosis
is the alloimmune response.
3.5. Risk factors for TxCAD
Several factors are known to promote TxCAD. Of immunological risk factors, the
frequency and intensity of acute rejection episodes and elevated levels of antibodies
against donor HLA molecules enhance TxCAD. There are also several antigen-
independent factors contributing to TxCAD such as donor brain death, long ischemic time,
reperfusion injury, cytomegalovirus infection, dyslipidemia, and diabetes. Immunologic
and nonimmunologic risk factors are summarized in Table 1.
Table 1. Risk factors for TxCAD
Risk factors Observations References
Experimental studies in Italics
Immunological
Acute rejection Frequency of rejection episodes,
intensity of acute rejection, and
late rejection episodes correlate with
severity of TxCAD
Uretsky et al., 1987; Narrod et
al., 1989; Radovancevic et al.,
1990; Schutz et al., 1990;
Nakagawa et al., 1995;
Mulla et al., 2001
Histoincompatibility HLA matching improves long-term
graft survival
Opelz et al., 1999
Panel reactive antibodies
(PRA)
Increased levels of antibodies
against donor HLA are associated to
TxCAD
Kerman et al., 1998
Non-immunological
Donor brain death Allografts from living donors have
reduced incidence of TxCAD
Anyanwu et al., 2003
Reperfusion injury Promotes TxCAD Knight et al., 1997; Schmid et
al., 1997; Wang et al., 2000
Cytomegalovirus infection Promotes TxCAD Grattan et al., 1989; Koskinen et
al., 1993; Lemström et al., 1993
Hypercholesterolemia Contributes to TxCAD
Combined hyperlipidemia enhances
aortic transplant arteriosclerosis
Statins reduce TxCAD
Alonso et al., 1977;
Raisanen-Sokolowski et al.,
1994;
Kobashigawa et al., 1995;
Wenke et al., 2003
Diabetes Contributes to TxCAD Hoang et al., 1998
Smoking Contributes to TxCAD Radovancevic et al., 1990
Hypertension Contributes to TxCAD Radovancevic et al., 1990
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3.6. Regulatory molecules
During the development of TxCAD many different cytokines and growth factors as well
as other signaling molecules are secreted by SMC, endothelial cells and inflammatory
cells, at the site of the vascular lesion. Detailed knowledge of the cytokine-growth factor
network is needed in order to find therapeutic tools to prevent TxCAD, but the interactive
network of signaling molecules is difficult to solve in detail despite the ability to block
single agents one by one using knockout animals or pharmacological products. Some of
the peptide growth factors and cytokines that may have a role in the pathogenesis of
TxCAD are summarized in Table 2.
Table 2. Factors with potential role in TxCAD
Molecules Observations References
Experimental studies in Italics
aFGF Expression correlates with severity of TxCAD Zhao et al., 1994; Miller et al.,
1999
AIF-1 Exclusively expressed in TxCAD Utans et al., 1995
Ang1 Ang1 overexpression reduces TxCAD Nykänen et al., 2002
CD28/B7 Blockade attenuates TxCAD Glysing-Jensen et al., 1997
CD40/CD154 Blockade attenuates TxCAD Wang et al., 2002
EGR-1 Targeted gene deletion reduces TxCAD Okada et al., 2002
ET-1 Increased expression in TxCAD
ET-1 receptor inhibition reduces TxCAD
Ravalli et al., 1996;
Okada et al., 1998
FAS Attenuates intimal thickening of aortic allografts Sata et al., 2001
IFN-γ IFN-γ deficiency reduces TxCAD Räisänen-Sokolowski et al., 1998
NO iNOS deficiency promotes, while enhanced NO
production attenuates TxCAD
Shears et al., 1997; Koglin et al.,
1998; Kown et al., 2001
p21 Overexpression reduces TxCAD Saiura et al., 2001
PAF Inhibition reduces TxCAD Crawford et al., 1999
PDGF Increased expression in TxCAD
Increased expression correlates with severity of
TxCAD
Zhao et al., 1994
Lemström and Koskinen, 1997
RANTES CCR1 receptor deficiency reduces TxCAD Gao et al., 2000
SERP-1 Decreases incidence of TxCAD Hausen et al., 2001
STAT-4 Targeted gene deletion reduces TxCAD Koglin et al., 2000
TF Expression correlates with the severity of TxCAD Yen et al., 2002
TGF-β TGF-β deficiency promotes TxCAD Koglin et al., 1998
TNF-α Blockade reduces early intimal lesions of cardiac
allografts
Clausell et al., 1994
TSP-1 Expression correlates with the severity of TxCAD Zhao et al., 2001
VEGF VEGF overexpression promotes TxCAD,
while VEGF-R inhibition reduces TxCAD
Associates to TxCAD
Lemström et al., 2002
Reinders et al., 2003
Abbreviations: EGR-1, early growth response gene-1; p21, cyclin dependent kinase inhibitor; PAF,
platelet activating factor; SERP-1, viral serine proteinase inhibitor-1, TF, tissue factor; TSP-1,
thrombospodin-1.
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Platelet-derived growth factor. PDGF is a polypeptide growth factor, originally purified
from platelets (Antoniades et al., 1979). Four different PDGF genes, PDGFA, PDGFB,
PDGFC, and PDGFD have been identified so far and all of them can be expressed by a
number of different cell types (Heldin et al., 2002). The functional products of PDGF
genes are homo- and heterodimers of disulfide-bonded A- and B-polypeptide chains while
the recently-found PDGFC and PDGFD gene-encoded polypeptides have been reported
to form only homodimers of PDGF-CC and PDGF-DD (Li et al., 2000; Bergsten et al.,
2001).
PDGF-AA PDGF-CC PDGF-AB PDGF-BB PDGF-DD
Ligand
isoform
Extra
cellular
Intra
cellular
Receptor
type α α α β β β
Figure 5 .  Different PDGF isoforms and their binding specificities to PDGF receptors. Functional
PDGF ligands are disulfide-bonded dimers which bind to dimerize α  and β receptors with different
specificities. Modified from Heldin et al. Arch Biochem Biophys. 2002;398:284-290, with the permission
of Elsevier Inc., New York, NY.
PDGF ligands act as dimeric molecules, which bind to and activate two protein tyrosine
kinase receptors, the PDGFR-α and PDGFR-β (Heldin and Westermark, 1999). The α-
receptor binds PDGF-A, PDGF-B and PDGF-C ligands, whereas the β-receptor binds
only PDGF-B and PDGF-D (Seifert et al., 1989; Li et al., 2000; Bergsten et al., 2001)
(Fig.5.). In ligand-receptor interaction two receptors are bound simultaneously as PDGF
ligands act as dimeric molecules. This receptor dimerization forms homo- or heterodimer
complexes of α- and β-receptors and allows autophosphorylation of tyrosine residues
between the two receptors resulting in a biological response.
PDGF is a major mitogen for vascular SMC and other cells of mesenchymal origin (Ross
et al., 1986). Studies with PDGF B ligand and β receptor knockout mice revealed that
PDGF and its receptors are essential for normal embryonic vascular development (Leveen
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et al., 1994; Soriano, 1994). PDGF has been demonstrated to carry angiogenic properties
(Battegay et al., 1994); however, the angiogenic effect is weaker than that of VEGF and
fibroblast growth factor. Although PDGF and its receptors are expressed at low levels in
normal human arteries (Barrett and Benditt, 1988), their expressions are increased in
several pathologic conditions, such as ordinary atherosclerosis (Libby et al., 1988; Rubin
et al., 1988; Wilcox et al., 1988), experimentally-induced atherosclerosis (Ross et al.,
1990; Golden et al., 1991), balloon catheter-injured arterial tissue (Majesky et al., 1990;
Kanzaki et al., 1994; Uchida et al., 1996), coronary arteries after percutaneous
transluminar coronary angioplasty (Ueda et al., 1996) and TxCAD (Zhao et al., 1994;
Lemström and Koskinen, 1997). Recent studies have demonstrated that neointimal
formation in balloon-injured rat and porcine arteries can be prevented using PDGF
inhibition with tyrosine kinase inhibitors selective for PDGF receptors (Myllärniemi et al.,
1997; Banai et al., 1998; Bilder et al., 1999; Yamasaki et al., 2001).
Endothelin-1. ET-1 is the most potent known vasoconstrictor released from endothelial
cells to act on the underlying vascular SMC (Yanagisawa et al., 1988). The effects of ET-1
are mediated via two G-protein-coupled receptors, the ET-RA and ET-RB. Ligand binding
results in the activation of intracellular phospholipase C and release of calcium from
sarcoplasmic reticulum leading to the ET-1 -dependent biological responses (Schiffrin and
Touyz, 1998). ET-RA receptors predominate in heart and vascular SMC, while ET-RB are
found in endothelial cells, kidney and central nervous tissue (Hosoda et al., 1991; Ogawa
et al., 1991; Molenaar et al., 1993; Maguire et al., 1994). In addition to its vasoactive
functions, ET-1 acts as a growth factor for SMC, and activated SMC themselves are
capable to produce ET-1 (Komuro et al., 1988; Hirata et al., 1989). Through these
vasoactive and mitogenic effects, the activation of ET-1 expression is connected to many
vascular disorders such as hypertension, atherosclerosis and TxCAD (Winkles et al.,
1993; Haynes et al., 1996; Ravalli et al., 1996). There are, however, controversial opinions
concerning the direct mitogenity of ET-1. Several studies indicate that ET-1 is promoting
SMC proliferation via PDGF action (Scott-Burden et al., 1991; Jahan et al., 1996; Yang et
al., 1999).
ET-1 protein levels are increased in atherosclerotic vessel wall as well as in the arterial wall
affected with TxCAD (Lerman et al., 1991; Watschinger et al., 1995; Ravalli et al., 1996).
IL-1β and TNF-α upregulate ET-1 mRNA levels in endothelial cells (Maemura et al.,
1992). In vascular SMC, PDGF-AA induces the production of ET-1 at protein and mRNA
levels (Hahn et al., 1990; Resink et al., 1990). In addition to having growth factor-like
properties, accumulating body of evidence suggests that ET-1 is also a proinflammatory
cytokine. It is known to prime neutrophils, activate mast cells, and stimulate monocytes to
22
produce a variety of cytokines such as IL-1β, IL-6, IL-8, and TNF-α (Yamamura et al.,
1994; Cunningham et al., 1997).
IL-1β and TNF-α. IL-1β together with TNF-α are first line proinflammatory cytokines
enhancing the level of local inflammation. They act in synergy and are produced mainly by
activated macrophages although several other cell types such as SMC, T and B
lymphocytes, cardiac myocytes and endothelial cells are also able to produce them (di
Giovine and Duff, 1990; Azzawi and Hasleton, 1999). IL-1β can act as a hematopoietic
growth factor and a stimulant of cellular and humoral immune responses (di Giovine and
Duff, 1990). During immune activation, a complicated network of proinflammatory and
anti-inflammatory cytokines regulate immune responses (Abbas et al., 1996). Anti-
inflammatory cytokines such as IL-4, IL-10, and IL-13 render helper T cell response
towards Th2 direction and tolerance, while INF-γ, IL-2, and TNF-α are linked to Th1
clones and proinflammatory activities (Abbas et al., 1996). TNF-α is able to trigger the
release of practically all known mediators of inflammation (Ferrari, 1999). It has a dual
role in many pathophysiological events; it may induce apoptosis not only in tumor cells
(Carswell et al., 1975) but also in myocardial cells, vascular SMC and endothelial cells
(Robaye et al., 1991; Geng et al., 1996; Krown et al., 1996). On the other hand, TNF-α
provokes hypertrophic growth response in human cardiac myocytes (Yokoyama et al.,
1997) and facilitates SMC growth by inducing PDGF release from cultured endothelial
cells (Hajjar et al., 1987).
During acute allograft rejection, both IL-1β and TNF-α mRNA levels are elevated in the
cardiac allograft (Dallman et al., 1991). Simultaneous treatment with antibodies against IL-
1β and TNF-α improved graft survival after experimental cardiac transplantation (Gerber et
al., 1995). Improved survival was achieved also by inhibition of either IL-1β by soluble IL-
1β receptor (Fanslow et al., 1990) or separate inhibition of TNF-α by anti-TNF-α
antibodies (Imagawa et al., 1991). Soluble IL-1β and TNF-α receptors are endogenous
anti-inflammatory immune modulators acting as counteragents for IL-1β and TNF-α. IL-
1β receptor antagonist had vasculoprotective effects on experimental occlusive arteritis and
clinical restenosis after coronary angioplasty (Nicklin et al., 2000; Francis et al., 2001). IL-
1β and TNF-α have been suggested to promote ordinary atherosclerosis by
proinflammatory mechanisms. IL-1β and TNF-α levels are increased in the human
atherosclerotic vascular wall (Barath et al., 1990; Galea et al., 1996). Both conventional and
allograft arteriosclerotic lesion formation are linked to increased expression of P-selectin
and vascular cell adhesion molecule–1 in endothelial cells possibly induced by TNF-α
(Johnson-Tidey et al., 1994; Koskinen and Lemström, 1997). Similarly, IL-1β enhanced
the production of adhesion molecules on endothelial cells of arteriosclerotic human
coronaries thereby increasing the recruitment of inflammatory cells into the vascular wall
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(Tamaru et al., 1998). Increased extracellular fibronectin synthesis by SMC is observed
during early stages of arteriosclerosis and is associated with accelerated SMC and
inflammatory cell migration during arteriosclerotic lesion formation (Clausell et al., 1993).
Both IL-1β and TNF-α stimulate fibronectin synthesis (Molossi et al., 1993; O'Blenes et
al., 2001) which is reduced by blocking either IL-1β or TNF-α (Clausell et al., 1994;
Hinek et al., 1996). Stimulated fibronectin synthesis is suggested to be one of the
atherogenic mechanisms mediated by IL-1β and TNF-α (Clausell et al., 1993; Clausell et
al., 1994).
3.7. Intervention of TxCAD
Today, clinical immunosuppressive treatment regimens for heart transplantation patients
are largely based on triple-drug immunosuppression with CsA/tacrolimus,
azathioprine/mycophenolate mofetil and glucocorticoids (Denton et al., 1999). Different
immunosuppressive drugs and their sites of actions are illustrated in Figure 6.
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Figure 6 .  Sites of action of different immunosuppressive drugs. Signal 1 indicates T cell receptor
triggering leading to intracellular calcium release and finally activation of cytokine transcription factors.
Signal 2 indicates costimulatory B7.1-CD28 mediated signal that is necessary for T cell activation.
Abbreviations: APC, antigen presenting cell; AZA, azathioprine; Ab, antibodies against T cells; CsA,
cyclosporin A; LFM, leflunomide; MHC, major histocompatibility molecule; MMF, mycophenolate
mofetil; MP, methylprednisolone; SIR, sirolimus; FK, tacrolimus; TCR, T cell receptor. Modified from
Halloran et al. J Heart Lung Transplant 1996;15:956-971, with the permission of Mosby-Year Book Inc.,
St Louis, MO.
24
Several immunosuppressive agents have inhibitory effects on TxCAD. Efficient dose/body
weight of CsA correlates with reduced TxCAD in clinical study (Gamba et al., 1997).
Tacrolimus is even more potent in preventing acute rejection and may further downregulate
TxCAD (Pham et al., 1996). MMF reduces chronic rejection of rat aorta (Räisanen-
Sokolowski et al., 1995) and sirolimus (rapamycin) has inhibitory effects on SMC
proliferation and migration (Marx et al., 1995; Poon et al., 1996). Everolimus, a derivative
of sirolimus, reduced the intensity and incidence of TxCAD compared to azathioprine in
clinical study (Eisen et al., 2003).
On the other hand, therapy with CsA is associated with several side-effects predisposing to
TxCAD and ordinary atherosclerosis including acute and chronic nephrotoxic effects,
hypertension and dyslipidemia (Denton et al., 1999). Corticosteroids have numerous well
known side-effects of which hypertension, dyslipidemia and glucose intolerance are most
harmful for cardiac allografts. Combination of CsA and methylprednisolone may
synergistically increase cardiovascular risk profile and predispose to TxCAD. The adverse
effects of glucocorticoids are often dose-dependent. In CsA based triple-drug maintenance
therapy, the dose of prednisone can be tapered down to as low as 5 mg/day and there are
several studies indicating that 50% of recipients can be safely weaned from steroids
(Keogh et al., 1992; Miller et al., 1992).
In an experimental study, TxCAD of cytomegalovirus-infected rats was prevented by
ganciclovir treatment (Lemström et al., 1997). In the clinical setting, a combination of
ganciclovir and CMV hyperimmune globulin treatment for seronegative recipients who
received a CMV seropositive heart, attenuated TxCAD (Valantine et al., 2001).
Sixty percent of cardiac transplant patients are hypercholesterolemic because of genetic
predisposition and metabolic alterations connected to immunosuppression. The respective
roles of these risk factors vary considerably from patient to patient. Clinical trials indicate
that HMG-CoA reductase inhibitors are beneficial in the reduction of TxCAD
(Kobashigawa et al., 1995; Wenke et al., 2003).
Elimination of other classical cardiovascular risk factors such as high blood glucose levels,
high blood pressure, and smoking, is considered important among heart transplant patients
although no clear-cut evidence for their influence on TxCAD has been established so far.
Hypertension develops in 60-80% of heart transplant patients due to use of
glucocorticoids and CsA. Of antihypertensive drugs, calcium channel blockers,
angiotensin II receptor inhibitors and angiotensin-converting enzyme inhibitors have been
shown to reduce intimal hyperplasia in clinical TxCAD (Schroeder et al., 1993; Mehra et
al., 1995; Furukawa et al., 1996).
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Table 3. Clinical and experimental interventions preventing TxCAD
Molecules Observations References
Experimental studies in Italics
Immunosuppressives
Cyclosporine A Reduces TxCAD
Low dose is a risk for TxCAD
Koskinen et al., 1995
Gamba et al., 1997
Everolimus Reduces TxCAD when compared to
Azathioprine
Eisen et al., 2003
Mycophenolate mofetil Reduces transplant arteriosclerosis in
rat aorta
Räisanen-Sokolowski et al.,
1995
Sirolimus (Rapamycin) Reduces TxCAD Goggins et al., 1996; Poston et
al., 1999; Mancini et al., 2003
Others
ACE inhibitor Reduces TxCAD Paul et al., 1994
Angiotensin II R inhibitor Reduces TxCAD Furukawa et al., 1996
Calcium channel blockers Reduces TxCAD Atkinson et al., 1993; Schroeder
et al., 1993
Ganciclovir Reduces CMV induced TxCAD. Lemström et al., 1997
Ganciclovir+CMV
hyperimmune globulin
Intensity and prevalence of TxCAD
was lower after 3 years in
Ganciclovir+CMVIG treated group
than group treated by Ganciclovir
alone.
Valantine et al., 2001
HMG-CoA reductase
inhibitors
Increase survival and decrease
incidence of TxCAD
Kobashigawa et al., 1995;
Wenke et al., 2003
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AIMS
The purpose of this study was to investigate crosstalk between PDGF and
proinflammatory cytokines (TNF-α, IL-1β, ET-1) during the development of TxCAD and
to identify new therapeutic tools to prevent this fibroproliferative disorder using
experimental rabbit and rat heart transplantation models and in vitro experiments.
Here, I specifically wanted
1. to investigate the role of PDGF and the interaction of IL-1β and TNF-α with
PDGF in TxCAD,
2. to investigate the role of PDGF in TxCAD in cholesterol fed rabbits,
3. to investigate the interaction of ET-1 and PDGF in TxCAD, and
4. to investigate the role of TNF-α in TxCAD.
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METHODS
1. Rat cardiac and aortic allograft models
Specific pathogen-free inbred DA (AG-B4, RT1a) and WF (AG-B2, RT1u) rats (200-
300g) (Laboratory Animal Center, University of Helsinki, Helsinki, Finland) were used as
donors and recipients in cardiac and aortic transplantations. The rats were fed with regular
laboratory rat food (Altromin, Standard Diœt, Chr. Petersen A/S, Ringsted, Denmark), and
drinking water was given ad libitum. Donor organs were harvested under deep ether
anesthesia. Recipients were anesthesized with chloral hydrate 240 mg/kg i.p., and were
given 0.1 mg/kg buprenorphine s.c. (Temgesic; Reckitt and Colman, Hull, UK) for
postoperative pain relief.
Heart. After ice-cold PBS heparin perfusion through vena cava inferior, caval vessels and
pulmonary veins of donor heart were ligated and aorta and pulmonary artery were cut 3-5
mm above their origin. Donor heart was preserved in ice-cold PBS for 15 min. Donor
heart aorta and pulmonary vein were anastomosed to recipient abdominal aorta and inferior
vena cava between renal vessels and bifurcation using a microsurgical technique modified
from Ono and Lindsey (Ono and Lindsey, 1969). Total ischemic time was 45±15 min
during which the donor heart was preserved inactive by cold PBS gauze. In a successful
operation, the graft started immediately vigorous pumping after circulation into the graft
was established.
Aorta. An approximately 3-cm long segment of the descending thoracic aorta was
removed, thoroughly perfused with PBS, and used as a transplant (Mennander et al.,
1991). A segment of the recipient´s abdominal aorta between renal vessels and bifurcation
was clamped, removed and replaced by the graft using end-to-end anastomosis. Total
ischemic time was 35±10 min, during which time the graft was kept in ice-cold PBS for
15 min and for the rest of the time the graft was cooled by ice cold PBS gauze.
2. Rabbit cardiac allograft model
In rabbit cardiac transplantation, specific pathogen-free outbred female Dutch Belted (1.5-
2 kg) and New Zealand White (2-3.5 kg) rabbit strains (Harlan, The Netherlands) were
used as donors and recipients, respectively. Four days before transplantation, 0.5 %
cholesterol diet was commenced (Altromin International, Lage, Germany). Donor hearts
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were harvested under ketamine 20 mg/kg, and medetomidin 300 mg/kg i.m. anesthesia.
The animals were given i.v. heparin and pentobarbital 30 mg/kg into the ear vein just
before cardiectomy. Ice-cold heparin PBS was infused into inferior vena cava and the heart
was harvested as described for the rat cardiac allograft model. Recipients were anesthetized
using ketamine 20 mg/kg, and medetomidin 300 mg/kg i.m., and buprenorfine 0.04 mg/kg
s.c. was given for postoperative pain. Before operation, recipients were given kefalotin
(Keflin, Eli Lilly Ltd., Vantaa, Finland) i.v. for prophylactic antibiotics and atropin for
hemodynamic stability. Allografts were transplanted heterotopically into cervical position
(Alonso et al., 1977). Aorta and pulmonary vein of donor heart were anastomosed end-to-
side to recipient´s common carotid artery and jugular vein, respectively. Total ischemic
time was 70±20 min of which the graft was preserved in ice-cold PBS for 30 min, and for
the rest of the time the graft was cooled by ice-cold PBS gauze.
3. Drug regimens
Cyclosporine A. CsA (Novartis, Basle, Switzerland) was dissolved in Intralipid solution
(Kabi Vitrum, Stocholm, Sweden) to a final concentration of 1-2 mg/ml for rats and 4
mg/ml for rabbits. CsA dose of 1, 1.5, 2, 3 or 4 mg/kg was administered once a day s.c.
starting at transplantation and continued until the end-point. Blood CsA 24-hour levels
were measured by radioimmunoassay (Sandimmune-Kit, Novartis).
PDGF receptor inhibition. CGP 53716, a protein tyrosine kinase inhibitor selective for
PDGF receptors (Novartis), was dissolved in DMSO to a concentration of 200 mg/kg and
diluted thereafter 1:20 with 1% Tween in 0.9% NaCl and sonicated. Rats received 50
mg/kg/d of CGP 53716 by a single i.p. injection starting 24 h before transplantation and
continued until the end-point. Control rats received an equal amount of vehicle prepared
and administered similarly as the drug. STI 571, a new generation orally-active PTK
inhibitor selective for PDGF receptors (Novartis), inhibits PDGF-R autophosphorylation
at the concentration of 1 µmol/l in vitro intact cells. Following oral administration of STI
571 50 mg/kg/d dissolved in saline, a peak plasma level of approximately 10 µmol/l was
obtained in the rat. Preliminary studies on rat tracheal allografts demonstrated that 5
mg/kg/d of STI 571 inhibited the development of airway occlusion as effectively as did 50
mg/kg/d of CGP 53716 indicating higher efficacy of the new molecule. Thus, the dose of
5 mg/kg/day, was chosen. STI 571 was dissolved in saline to a concentration of 5 mg/ml
and administered for rabbits once a day 5 mg/kg i.p.
Soluble TNF-α receptor. Rat cardiac allograft recipients were given soluble TNF
receptor p80/IgG1 Fc fusion protein (TNF-RII:Fc) (Immunex Co, Seattle, WA) or human
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IgG (huIgG) (Sigma Chemical Co., St. Lois, MO) at a dose of 2 mg/kg/d i.p. every other
day for 10 times.
Endothelin-1 receptor inhibition. Rat cardiac allograft recipients were given bosentan
(Ro 47-0203/029), an orally active nonpeptide endothelin antagonist (Actelion Ltd,
Allschwil, Switzerland) or vehicle, at a concentration of 25 mg/ml with a dose of 100
mg/kg/day for the whole follow-up. Bosentan was suspended in 5 % gummi arabicum and
given by gavage trough orogastric tube. The stock solutions and dilutions were prepared
daily prior to administration.
4. Histological and immunohistological evaluation
Histology. Changes in intimal thickness were scored from Mayer´s hematoxylin-eosin
and Resorcin fuchsin stained cross sections according to Billingham's criteria: grade 0,
normal artery with intact internal elastic lamina; grade 1, < 10% occlusion of lumen by
arterial intimal thickening and proliferation, disruption of internal elastic lamina, some
foam or vacuolated endothelial cells may be present; grade 2; <50% occlusion of the
lumen; grade 3, >50% but <100% occlusion of lumen; and grade 4, 100% vessel occlusion
of lumen.
Lesions in proximal ascending aorta, the site of early arteriosclerotic lesion involvement in
cholesterol-fed rabbits, were also analyzed. Histological changes were quantitated using a
microscope ocular grid at 400 times magnification. The intima/media ratio was quantitated
using a Macintosh NIH image software. The picture from the microscope was transferred
to the screen with an Olympus video microscope with 25x magnification. The areas inside
the internal elastic lamina, external elastic lamina, and of the aortic lumen were measured,
and the intima/media area ratio was calculated from these values. The number of medial
cells per cross section was quantitated to evaluate the degree of media necrosis.
Immunohistochemistry. For single stainings, frozen sections were incubated with 1.5%
nonimmune serum followed by incubation with primary mouse monoclonal antibodies at
room temperature for 30 to 60 min or with rabbit or goat polyclonal antibodies at +4°C for
12 h. With intervening washes in Tris-buffered saline, the following steps were performed:
biotinylated horse anti-mouse, goat anti-rabbit, rabbit anti-goat or rabbit anti-sheep
absorbed antibodies at room temperature for 30 min; avidin-biotinylated horse-radish
complex (Vectastain Elite ABC Kit, Vector Laboratories, Burligame, CA) in PBS at room
temperature for 30 min; the reaction was revealed by chromogen 3-amino-9-ethylcarbazole
(AEC; Sigma) containing 0.1% hydrogen peroxidase, yielding a brown-red reaction
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product. The specimens were counterstained with hematoxylin and coverslips were
aquamounted (Aquamount; BDH Ltd., Poole, UK). Specificity controls were performed
by stainings using the same immunoglobulin concentrations of species and isotype-
matched antibodies and staining after overnight incubation with a 10 to 20-molar excess of
recombinant cytokines or peptides. Antibodies, their specificities, sources, and dilutions
used in immunostainings are given in the original publications I-IV.
Quantitation of immunohistochemistry. The immunohistochemical analysis was done
in a blind review by two observers. The score assigned was determined by consensus of
the observers. The intensity of the staining was scored from 0 to 3 as follows: 0, no visible
staining; 1, few cells with faint staining; 2, moderate intensity with multifocal staining; and
3, intense diffuse staining of the cells analyzed.
5. Gene expression analysis
5.1 Total RNA isolation
Total RNA isolation from fresh heart segments was performed using the guanidine-
isothiocyanate preparation (Chomczynski and Sacchi, 1987). After isolation and
purification, RNA concentrations were measured by a spectrophotometer and the quality
of RNA was confirmed by electrophoresis trough 1 % agarose.
5.2 Semiquantitative RT-PCR
Total RNA was reverse transcribed to cDNA in master mix containing 1xRT buffer
(Promega, Madison, WI), dNTP (GeneAmp; Perkin Elmer, Foster City, CA), oligo-dT
primer (p(dT)15 primer, (Boehringer-Mannheim, Mannheim, Germany), RNasin (RNasin
Ribonuclease Inhibitor; Promega), and reverse transcriptase (M-MLV-RTase Reverse
Transcriptase, RNase H Minus; Promega). The cDNA reaction mixture was added with
water and supplemented 10xPCR buffer I (GeneAmp; Perkin Elmer), dNTP (GeneAmp;
Perkin Elmer), α32P-dATP 3000 Ci/mmol (Amersham, Buckinghamshire, UK), sense
primer, antisense primer, and AmpliTaq Gold (Perkin Elmer). After 33-37 cycles in a 96-
well PCR apparatus (GenAmp PCR System 9600 apparatus; Perkin Elmer), the samples
were electrophoresed through 2% agarose. The gel was dried (LKB 2003 Slab Gel Dryer,
LKB, Bromma, Sweden), exposed to imaging plate (Fuji Photo Film Co., Tokyo, Japan)
and the gels were quantified using a Fuji BAS1500 phosphoimager. The mean values of
three determinations were used for final analysis and the normalized mRNA levels were
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derived by dividing the mean of the mRNA of the gene of interest by the mean of GAPDH
mRNA for each tissue sample. To identify the optimal PCR conditions for accurate
measurement of each gene transcript, a logarithmic assay range with respect to cycle
number for each primer was established by performing a series of PCR analysis from the
samples under investigation by linearly increasing the cycle number. The cycle number for
each primer was chosen from the linear part of the S-slope. The sequences, cycle numbers,
and accession numbers are given in the original publications (I,III,IV). The primers were
prepared at Molecular/Cancer Biology Laboratory, Department of Pathology, University of
Helsinki, Helsinki, Finland.
5.3 Quantitative RT-PCR
Rat coronary SMC were challenged either with IL-1ß or TNF-α or vehicles for 4 h (see
below) and total RNA was extracted as described above. Six serial dilutions were made
with an appropriate amount of total RNA from each preparation, mixed with either 106 or
107 molecules of synthetic template RNA containing a 46 nucleotide insert and reverse
transcribed to cDNA in a mixture containing 1x RT buffer, 300 mM dNTP, 10 pmol of
antisense primer, 20 U RNasin and 100 U of reverse transcriptase at +37°C for 90 min.
Two ml of cDNA mixture were supplemented with 10x PCR buffer, radioactive tracer, 10
pmol of antisense primer, 10pmol of sense primer and 2.5 U of Taq polymerase. The
samples were heated to +95°C for 5 min and cycled 40 times (+94°C for 30 sec, +60°C
for 30 sec and +72°C for 1 min). The PCR samples were electrophoresed through 2%
agarose gel, the fragments of interest were cut off the gel and incorporated radioactivity
was counted using the Cherenkov counting protocol. The primer sequences are given in
the original publication (I).
6. Cell cultures
A cultured rat coronary artery SMC line originating from Dr. C.A. Diglio (Wayne State
University, Detroit, MI), provided by Dr. Dariusz Leszczynski (Finnish Center for
Radiation and Nuclear Safety, Helsinki, Finland), was used for proliferation and migration
assays as well as for mRNA level quantitation of growth factors and their receptors. For
proliferation analysis, the cells were trypsinized and seeded on 32 cm2 microwells in
culture medium containing 10% FBS at a concentration of 25000 cells/ml and allowed to
adhere for 24 h. After starvation in serum-free medium for 72 h, the quiescent cells were
either incubated with 20-60 ng/ml of PDGF-AA, PDGF-AB and PDGF-BB (Upstate
Biotechnology Inc., Lake Placid, NY) for 24 h, or also preincubated with 10 ng/ml of ET-1,
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IL-1β or TNF-α (Peninsula Laboratories Inc., Belmont, CA) in 0.5% FBS in DMEM
supplemented with 0.1% BSA for 24 h. [3H]TdR-incorporation (1 µCi/ml) was measured
with a Rackbeta liquid scintillation counter (LKB-Wallac) during the final 24 h incubation.
For migration analysis, Transwell culture chambers (Costar) were coated with collagen
(Upstate Biotechnology Inc.) and 50000 cells were seeded in the upper chamber. After 2h,
ET-1, PDGF-AA, PDGF-AB and PDGF-BB were added to the lower chamber and
incubated at +37°C for 24 h. The filters were fixed in methanol, stained with Mayers
hematoxylin and removed. Migrated cells on the lower side of the filter were quantitated by
counting specified cross-sectional fields with a light microscope using 40 x magnification.
For mRNA analysis, the cells were starved for 72 h in 0.5% FBS DMEM supplemented
with 0.1% BSA. The quiescent cells were challenged with 20 ng/ml ET-1, washed with
PBS and harvested in guanidine-isothiocyanate buffer at 4 h. RNA isolation was
performed as described above.
7. Statistical analyses
All data are given as mean ± SEM. A nonparametric test was chosen because of the small
sample sizes and inability to determine whether the samples were normally distributed.
The Mann-Whitney U test, z corrected for ties (Statview 4.1 program; Abacus Concepts,
Berkeley, CA), was used to evaluate the significance between two groups. For multiple
comparison, Kruskal Wallis and Dunn tests were applied. The rank sums obtained by the
Kruskal Wallis test were used for the Dunn test at the significance level of 5% or 1%
(Medstat, Astra Group A/S, Arbetslund, Denmark). Graft survival between the groups was
analyzed by log rank test (Medstat; Astra Group A/S). In addition, linear regression
analysis was applied to evaluate the possible relation of growth factor ligand and receptor
expression to intimal thickening. Values of P<0.05 were regarded as statistically
significant.
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RESULTS
1. Effect of CsA on the development of TxCAD in rat and rabbit cardiac
allografts (I-IV and unpublished observations)
To investigate the mechanisms of TxCAD, we developed allogeneic rat and rabbit cardiac
transplantation models. To achieve slowly-developing nondestructive arterial lesions with
high resemblance to those observed in man, CsA background immunosuppression was
used. We observed a dose- and concentration-dependent inhibitory effect of CsA on the
development TxCAD in rats (Fig.7.).
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Figure 7 .  The effect of CsA dose (A) and trough level (B) on the development of TxCAD. Grade
indicates mean value of arterial intimal thickness by semiquantitative scoring from 0 to 4. In the lower
panels (C), photomicrographs of typical vascular wall changes under different doses of CsA.
2. Role of PDGF and the interaction of IL-1β and TNF-α with PDGF in TxCAD
(I)
To study the role of PDGF in TxCAD we used CGP 53716, a tyrosine kinase inhibitor
selective for PDGF receptors, in rat cardiac allograft recipients with CsA
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immunosuppression. As CGP 53716 increased serum CsA trough levels, CsA doses were
adjusted according to blood levels. CGP 53716 significantly reduced both the intensity
and incidence of cardiac allograft arteriosclerosis. To exclude the effect of CsA, the results
were confirmed in the aortic allograft model without CsA. CGP 53716 significantly
attenuated intimal thickening and the intima/media ratio in aortic allografts, but it had no
effect on the influx of CD4+, CD8+, or ED1+ cells into the graft.
To further investigate the role of different PDGF ligands and receptors as regulators of
SMC proliferation, cultured rat coronary artery SMC were prestimulated with
proinflammatory cytokines and thereafter stimulated to grow by either PDGF-AA or
PDGF-BB. Without prestimulation the PDGF-BB ligand was a more potent mitogen than
PDGF-AA but when prestimulated with TNF-α or IL-1β, the mitogenity of PDGF-AA
ligand was raised up to the level of PDGF-BB. CGP 53716 significantly inhibited
proliferation induced by both cytokine-primed and merely PDGF-AA or PDGF-BB
ligand-induced proliferation. To explain the observed differences in the response patterns
of cytokine-primed and non-primed SMC, we challenged rat coronary SMC with IL-1ß
and TNF-α for 4 h and quantitated the mRNA transcript levels of PDGF ligands and
receptors. IL-1ß induced a 60-fold and TNF-α a 100-fold upregulation of PDGF-Rα
mRNA expression in SMC, whereas the levels of PDGF-A, -B, and -Rβ remained
unchanged.
3. Effect of PDGF receptor inhibition on TxCAD in cholesterol-fed rabbits (II)
We also investigated whether PDGF inhibition reduces cardiac allograft arteriosclerosis in
hypercholesterolemic rabbits. STI 571, a new generation analogue of CGP 53716, was
used. STI 571 is an orally active protein tyrosine kinase inhibitor selective for PDGF
receptors. In rabbit cardiac allografts, STI 571 significantly reduced both the incidence and
intensity of cardiac allograft arteriosclerosis in medium-sized coronary arteries. STI 571
also decreased intimal thickening and the intima/media ratio in ascending aortas of cardiac
allografts. Of interest was the finding that STI 571 attenuated changes of ordinary
atherosclerosis in medium-sized arteries of host hearts as well .
4. Effect of ET-1 on the development of TxCAD (III)
In long-term surviving rat cardiac allografts, ET-RA protein expression in intimal cells
correlated with intimal thickening and ET-RB protein expression in intimal and medial
cells correlated with intimal thickening. During acute rejection, ET-1 ligand was
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upregulated in mononuclear inflammatory cells and both receptors were upregulated in
medial cells compared to normal heart and syngeneic controls. Furthermore, both ET-RA
and ET-RB mRNA expression was significantly increased in chronically rejecting
allografts compared with syngeneic controls. The biological significance of ET-1 in
TxCAD was investigated using bosentan, a selective antagonist for both ET-1 receptors.
Treatment with bosentan significantly reduced the amount of affected vessels, and the
mean grade of intimal thickening. In chronically rejecting cardiac allografts, bosentan
treatment significantly decreased the mRNA expression of PDGF-Rβ, while the mRNA
expression of PDGF-A, –B and -Rα remained unchanged at 60 days after transplantation.
To explain the beneficial effects of bosentan on TxCAD, we challenged rat coronary artery
SMC with ET-1 for 4 h and quantitated the mRNA transcript levels of PDGF ligands and
receptors. ET-1 stimulation upregulated the expression of PDGF-Rα and -Rβ mRNA in
cultured SMC but the mRNA expression of PDGF-A and -B ligands remained
unchanged.
On stimulation with either ET-1, PDGF-AA, PDGF-AB or PDGF-BB alone, there was an
1.5-, 2-, 3- and 4-fold increase observed in SMC [3H]-TdR-incorporation, respectively.
When SMC were prestimulated with ET-1 for 24 h, only PDGF-BB, but not PDGF-AA
nor –AB, significantly (P<0.001) upregulated [3H]-TdR-incorporation in SMC.
ET-1 and PDGF-AA stimulation had no effect on SMC migration, whereas PDGF-AB
and PDGF-BB stimulation induced a 3-fold increase in SMC migration. When SMC were
prestimulated with ET-1, PDGF-AA had no additive effect on SMC proliferation, whereas
PDGF-AB and PDGF-BB significantly upregulated SMC migration.
5. Effect of TNF-α on the development of TxCAD (IV)
There was a 2- and 3-fold increase detected in TNF-α and TNF-R2 mRNA expression in
acutely rejecting allografts compared with syngeneic grafts, respectively. In cardiac
allografts with severe intimal thickening, a significant induction of TNF-α and TNF-R2
mRNA was observed 60 days after transplantation compared with similarly
immunosuppressed syngeneic grafts. Induced immunoreactivity for TNF-α and TNF-R2
was evident during acute rejection episodes and in allografts with severe arteriosclerotic
changes. Immunoreactivity was localised into medial cells of arterial wall and into
inflammatory cells.
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Rat cardiac allograft recipients were treated either by recombinant human soluble TNF
receptor p80/IgG1 Fc fusion protein (rhu TNF-RII:Fc) to inhibit TNF-α –mediated
pathway or by human IgG in the control group. Inhibition of TNF-α pathway did not
affect graft survival nor reduce the incidence or intensity of arteriosclerotic changes
compared with human IgG-treated allografts. However, TNF-RII:Fc significantly inhibited
myocardial remodeling observed as a decrease in hypertrophic growth response of the
myocardium. Both midsectional area of allografts and cross-sectional area of single
cardiomyocytes were smaller in allografts treated by TNF-RII:Fc. Treatment with TNF-
RII:Fc had no effect on immunohistochemically observed TNF-α expression in the vessel
wall, but it significantly downregulated TNF-α expression in cardiomyocytes.
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DISCUSSION
Cardiac allograft arteriosclerosis as a manifestation of chronic rejection is the leading
cause of morbidity and mortality among cardiac transplant recipients one year after
transplantation. TxCAD is a multifactorial disease where alloimmune response plays a
central role (Libby and Pober, 2001). Despite novel immunosuppressive therapies,
progression of the disease is inevitable among most patients. Although clinical and
experimental studies have yielded valuable data, the exact pathophysiological mechanisms
leading to TxCAD are not understood and we have no preventive tools available.
1. Experimental heterotopic cardiac transplantation as a preclinical model to
study TxCAD
To investigate the mechanisms of TxCAD, a modified heterotopic rat cardiac
transplantation model was developed from the model of Ono and Lindsey (Ono and
Lindsey, 1969). In order to closely mimic the current clinical immunosuppression, in our
model recipient rats initially received oral triple drug immunosuppression with CsA,
methylprednisolone, and azathioprine. As CsA was observed to be crucial in avoiding
destructive acute rejections and intimal thickening due to chronic rejection, CsA
monotherapy was used as background immunosuppression (Koskinen et al., 1995).
Thereafter, the bias caused by variations in CsA blood levels was eliminated by
commencing daily s.c. injections of CsA instead of administering the drug with regular rat
food (Lemström et al., 1997).
2. PDGF-Rα activation plays a pivotal role in TxCAD in the presence of TNF-α
and IL-1β
We have previously observed a strong positive correlation between vascular PDGF ligand
and receptor immunoreactivity and the severity of TxCAD in the rat (Lemström and
Koskinen, 1997). Especially PDGF-AA ligand was upregulated in the medial cells of
arterial wall during alloimmune activation and its expression as well as that of PDGF-Rα
and PDGF-Rβ in the neointima correlated with the severity of TxCAD. In clinical settings,
increased expression of PDGF-AA ligand and PDGF-α receptor was detected by in situ
hybridisation in vascular structures of human cardiac allografts (Zhao et al., 1995). In our
study, selective inhibition of PDGF receptor tyrosine kinase by CGP 53716 reduced
intimal lesion formation in rat cardiac allografts suggesting a novel therapeutic strategy for
TxCAD (I).
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Our observations in rat cardiac allografts suggest a pivotal role for PDGF-AA in TxCAD
(I), although PDGF-BB is the most potent known mitogen for SMC in vitro (Thyberg et
al., 1990). The in vitro results show that prestimulation with TNF-α or IL-1β render SMC
equally responsive to PDGF-AA whereas prestimulation does not significantly alter the
responses to PDGF-BB. This is explained by PDGF-Rα upregulation as the PDGF-Rα
mRNA levels of cultured SMC were increased 100- and 60-fold upon prestimulation with
TNF-α and IL-1β, respectively. In addition, CGP 53716 efficiently reduced IL-1ß and
TNF-α primed SMC proliferation induced by PDGF-AA. Since the concentration of CGP
53716 used was suboptimal (50% inhibition) in inhibiting PDGF-Rß but optimal (total
inhibition) in inhibiting PDGF-Rα (Myllärniemi et al., 1997), the results suggest that
TNF-α induced response to PDGF-AA is mediated by PDGF-Rα. Enhanced expression
of PDGF-AA in response to TGF-ß, IL-1ß and TNF-α in EC and SMC with
simultaneous peak of SMC proliferation is demonstrated by previous studies (Hajjar et al.,
1987; Raines et al., 1989; Battegay et al., 1990). Together, these data strongly suggest that
PDGF-Rα activation pathway in the presence of TNF-α and IL-1β is one of the crucial
regulatory pathways in the development of TxCAD (I).
Consistent with the results of this study is that the same compounds also significantly
reduced experimental obliterative bronchiolitis, i.e., chronic rejection of transplanted lung
and neointima formation of balloon injured rat carotid artery model (I; Myllärniemi et al.,
1997; Kallio et al., 1999). In aortic transplantation and other arterial injury models,
inhibition of PDGF PTK successfully decreased neointima formation as well (Banai et al.,
1998; Bilder et al., 1999; Yamasaki et al., 2001; Karck et al., 2002). In addition to PDGF
receptor PTK, CGP 53716 is reported to inhibit c-kit receptor PTK (Heinrich et al., 2000).
However, no c-kit immunoreactivity was seen in our models of cardiac allografts with
either acute or chronic rejection. CGP 53716 did not affect graft survival in the acute
rejection model nor did it affect the inflammatory cell influx into the grafts. Thus, it seems
that CGP 53716 selectively inhibited PDGF-R protein-tyrosine kinase, and SMC
migration and proliferation in our model, but did not mediate its effect by downregulating
the alloimmune response (I).
3. PDGF inhibition reduces TxCAD in the presence of hypercholesterolemia
Previous studies suggested that hypercholesterolemia may increase neointimal formation
by regulating PDGF expression in monocytes and ET-1 expression in endothelial cells
and thereby upregulate PDGF receptor expression in SMC (Bath and Martin, 1991; Billett
et al., 1996). As rats are virtually resistant to hypercholesterolemia, we tested the role of
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PDGF in hypercholesterolemia-enhanced TxCAD in the rabbit cardiac allograft model.
The results demonstrate that STI 571, a selective PDGF receptor PTK inhibitor, reduces
TxCAD in cholesterol-fed rabbits (II). The results show also that STI 571 inhibits
cholesterol-induced accelerated arteriosclerosis in coronary arteries of recipient´s own
heart. In vivo, endogenous neutralizing antibodies against PDGF-AA reduce intimal
thickening of cholesterol-fed rabbit aorta (Lamb et al., 2001). However, specific antibody
treatment targeted to PDGF-Rα only minimally reduced aortic intimal lesions of
apolipoprotein deficient mice, whereas blockade of PDGF-β reduced intimal lesion size by
67% in the same setting (Sano et al., 2001). Hence, both PDGF-R-ligand pairs are likely
to play important regulatory roles in SMC proliferation leading to TxCAD.
4. Origin of neointimal SMC reveals new roles for PDGF in TxCAD
Recent findings suggest that neointimal SMC in TxCAD may also originate from recipient
SMC progenitors (Hillebrands et al., 2000; Li et al., 2001; Saiura et al., 2001; Shimizu et
al., 2001). PDGF-BB is implicated in embryonic SMC differentiation and migration
(Hellstrom et al., 1999). Study with embryonic vascular stem cells revealed a common
vascular stem cell type able to differentiate either to SMC or EC under balanced regulation
of PDGF-BB and VEGF, respectively (Yamashita et al., 2000). In addition of being an
important regulator of vasculogenesis, VEGF is a proinflammatory molecule (Barleon et
al., 1996; Neufeld et al., 1999) and is proven to have a role in the development of TxCAD
(Lemström et al., 2002). Blocking of both PDGF and VEGF pathways was twice as
efficient to reduce TxCAD than blocking of either pathway alone (A. Nykänen, personal
communication). Therefore, PDGF-BB together with VEGF may regulate recruitment and
differentiation of neointimal cells.
5. PDGF-Rβ activation pathway plays a pivotal role in TxCAD in the presence of
ET-1
Several clinical findings suggest a role for ET-1 as a SMC regulating growth factor in the
pathogenesis of ordinary CAD and TxCAD. ET-1 protein levels are elevated in neointimal
arteriosclerotic lesions of human transplanted and nontransplanted heart correlating with
the severity of lesions (Zeiher et al., 1994; Ravalli et al., 1996). A recent observation that
nonpeptide ET-1 receptor antagonist bosentan, which blocks both ET-RA and ET-RB,
significantly reduced experimental TxCAD (Okada et al., 1998) was parallel to our results
(III). Furthermore, selective ET-RA antagonism reduced neointimal hyperplasia in a
porcine coronary stent model and prevented ET-1 induced mitogenesis in rat cultured
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SMC suggesting that the pathophysiologic action of ET-1 in proliferative SMC disorder is
mediated via ET-RA (McKenna et al., 1998; Yang et al., 1999).
Results concerning the mitogenic properties of ET-1 are controversial. Several studies
consider ET-1 as a direct mitogen for SMC (Komuro et al., 1988; Hirata et al., 1989)
whereas others regard the mitogenity of ET-1 as a PDGF-mediated event (Scott-Burden et
al., 1991; Jahan et al., 1996; Yang et al., 1999). Our in vitro results show that ET-1 alone is
a weak mitogen for SMC (III). However, prestimulation of cultured SMC with ET-1
induced a strong co-mitogenic effect with PDGF-BB. It induced also PDGF-Rα and
PDGF-Rβ mRNA upregulation pointing out that ET-1 augments the neointimal growth
indirectly via PDGF receptor upregulation. Although both PDGF receptors were
upregulated in response to ET-1 prestimulation, the proliferative response of SMC to
PDGF-AA and PDGF-AB remained unaltered indicating that ET-1 promotes in particular
PDGF-BB mediated SMC proliferation. Similar potentiation of PDGF-BB induced SMC
proliferation by ET-1 was also observed by others (Yang et al., 1999). These findings were
consistent with in vivo observations where bosentan decreased PDGF-Rβ expression in
cardiac allografts but CGP 53716 did not reduce the intragraft levels of preproET-1, ET-
RA or ET-RB mRNA. Hence, both in vitro and in vivo results speak for the priming
function of ET-1 in PDGF-BB mediated signaling (III).
6. Inhibition of TNF-α attenuates myocardial remodeling but not TxCAD
It has been shown in this study (IV) and by others that cardiac myocytes are able to
produce substantial amounts of TNF-α (Kapadia et al., 1995) and that TNF-α is a
cytokine capable of stimulating cardiac growth (Kubota et al., 1997; Yokoyama et al.,
1997; Bozkurt et al., 1998). A recent clinical study demonstrated that increased myocyte
size was associated with persistently expressed TNF-α in cardiac allografts but not in
normal myocardium (Stetson et al., 2001). Although an accumulating body of evidence
suggests a role for TNF-α as a mediator of hypertrophy, direct proof is still lacking. In
this study, we found decreased cardiomyocyte size in cardiac allografts with concomitant
reduction in TNF-α immunoreactivity in response to TNF-R2:Fc treatment. There was
neither difference in fibrosis nor inflammatory cell influx into allografts suggesting that
cardiomyocyte hypertrophy of allografts is mediated by TNF-α (IV).
Previous findings suggest that TNF-α has a regulatory role in the acute rejection and early
neointimal formation seen after experimental cardiac transplantation (Clausell et al., 1994).
Elevated TNF-α levels have been observed in intimal cells of human arterial wall with
atherosclerosis (Barath et al., 1990; Rus et al., 1991). TNF-α induces a substantial
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increase in the expression of intercellular adhesion molecule (ICAM) in cultured human
SMC and EC (Couffinhal et al., 1993). In vivo, the intensity of both VCAM-1 and P-
selectin expression correlated with the severity of intimal lesions of cardiac allografts
(Koskinen and Lemström, 1997). This upregulation of endothelial P-selectin and VCAM-
1 coincided with the elevated expression of TNF-α suggesting that TNF-α regulates the
inflammatory cell recruitment into the vascular wall. We and others have showed that
TNF-α upregulates PDGF-Rα in SMC and potentiates PDGF-AA induced SMC
proliferation in vitro (I; Hajjar et al., 1987). However, treatment with TNF-R2:Fc failed to
prevent TxCAD in our model indicating that TNF-α, despite its active role in alloimmune
activation, is not a rate-limiting cytokine for SMC proliferation in TxCAD. The sustained
PDGF immunoreactivity during the inhibition of TNF-α pathway (IV) may explain the
lack of its effect on SMC proliferation. Other proinflammatory cytokines may also
compensate the missing TNF-α.
7. Conclusions
The findings in this series of work (I-IV) support the modified response-to-injury
hypothesis, where the arterial network of cardiac allografts is occluded by neointimal
growth due to a repairing process compensatory for continuous series of damage against
the vascular wall (Libby and Pober, 2001). Endothelial cells, SMC, macrophages, and T
cells present during the development TxCAD release growth factors that regulate SMC
and extracellular matrix accumulation into the neointima in proinflammatory cytokine
environment. Recent experimental findings demonstrate that instead of medial origin
intimal SMC may derive from the recipient´s circulation (Hillebrands et al., 2000; Li et al.,
2001; Saiura et al., 2001). Endothelial cell injuries independent of the etiology are crucial
elements leading to TxCAD. In the context of cardiac transplantation, a series of
endothelium injuries is inevitable. Blood pressure changes-, ischemia-, and reperfusion-
induced injuries pre- and perioperatively are followed by a direct alloimmune response.
When donor APC are exhausted and the direct alloimmune response vanishes, alloimmune
activation may be maintained by activated macrophages and T helper cells in the delayed-
type hypersensitivity reaction. The continuous series of injuries and compensatory
cytokine and growth factor release lead to obliterative SMC accumulation into arterial
intima and luminal occlusion. This study identifies PDGF as a key regulatory molecule in
the formation of arteriosclerotic lesion in TxCAD and suggests that proinflammatory
cytokines such as TNF-α, ET-1 and IL-1β may mediate their effect on TxCAD by PDGF
receptor upregulation in SMC (Fig. 8.). However, blocking of the PDGF pathway is not
sufficient to totally prevent TxCAD. Recent findings show that inhibition of PDGF and
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VEGF pathways in combination is highly efficient to prevent TxCAD indicating that a
molecule able to block several growth factors might be the breakthrough.
TNF-α
IL-1β
ET-1
SMC
SMC
Macrophage
PDGF-Rα PDGF-Rα PDGF-Rβ
PDGF-AAPDGF-AA
EC
PDGF-BB
INJURY
T cell
PDGF-AA/BB
Figure 8. Crosstalk between PDGF and proinflammatory cytokines leading to SMC accumulation into
arterial wall. Immune- and nonimmune-mediated injuries activate endothelial cells to express adhesion
molecules, cytokines and growth factors. Adhesion molecules and cytokines induce inflammatory cell
recruitment into the arterial wall. Inflammatory and endothelial cells produce cytokines such as TNF-α,
IL-1β and ET-1 as well as PDGF ligands. TNF-α and IL-1β upregulate PDGF-Rα on SMC whereas ET-1
upregulates PDGF-Rβ. As a consequense of PDGF receptor upregulation response to PDGF ligands is
strenghtened. This results in SMC proliferation and influx into neointima and intimal thickening.
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